Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07275315 in Inadequately Controlled Moderate-to-Severe Asthma
NCT06977581Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- May 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of tilrekimig in asthma, sponsored by Pfizer. Started May 2025; status: recruiting.
02
Drugs
tilrekimig
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06977581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06977581.